Clovis Oncology to highlight Rubraca and Lucitanib non-clinical data at AACR virtual annual meeting June 22-24

Clovis Oncology to highlight Rubraca and Lucitanib non-clinical data at AACR virtual annual meeting June 22-24

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand... Read More

Wednesday June 17, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca, Lucitanib

Clovis Oncology announces completion of target enrollment in Phase 3 ATHENA trial

Clovis Oncology announces completion of target enrollment in Phase 3 ATHENA trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca ... Read More

Thursday June 11, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer

Clovis Oncology announces new recommendations for Rubraca for treatment of metastatic castration-resistant prostate cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS), today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to... Read More

Friday May 29, 2020 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy

Clovis: Rubraca approved in U.S. for treatment of BRCA1/2-Mutant, metastatic castration-resistant prostate cancer

Clovis: Rubraca approved in U.S. for treatment of BRCA1/2-Mutant, metastatic castration-resistant prostate cancer

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca ® (rucaparib) tablets for the treatment of adult patients with a... Read More

Monday May 18, 2020 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces Rubraca cancer drug available in France

Clovis Oncology announces Rubraca cancer drug available in France

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in France. Rubraca is an option for monotherapy maintenance treatment... Read More

Monday February 3, 2020 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis updates data on Rubraca clinical trial

Clovis updates data on Rubraca clinical trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the... Read More

Monday September 30, 2019 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology names Ginger Graham board chair

Clovis Oncology names Ginger Graham board chair

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the appointment of Ginger L. Graham as chair of the companys board of directors following the retirement of former board chair Dr. ... Read More

Friday June 7, 2019 0 comments Tags: Boulder, Clovis Oncology, Ginger Graham, Patrick J. Mahaffy

Clovis Oncology to receive $175M to fund company’s largest clinical trial

Clovis Oncology to receive $175M to fund company’s largest clinical trial

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG... Read More

Thursday May 2, 2019 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, TPG Sixth Street Partners, ATHENA study, Rubraca